Trading in Dendreon Corp. (Nasdaq: DNDN) remained volatile as investors mulled over the possibility of a congressional probe into the hastily withdrawn approval of a promising cancer drug which had received strong market support from cancer patients. The stock price dropped 68 cents to $6.65.
Congress To Probe Withdrawn Approval Of Dendreon Drug
December 17, 2007 at 12:32 PM EST
